Engflag

C-Tax

Quick links to important sections

C-Tax

C-Tax_EN

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal

Treatment option: Bacteremia, Lyme Disease, Gonorrhea, Immunodeficiency, Infection, Fever, Meningitis, Peritonitis, Sepsis, Surgery

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of C-Tax

What is C-Tax? An Identity Overview

Here is a quick overview of the key facts defining C-Tax (Cefotaxime).

Property Description
Active Ingredient Cefotaxime (as the sodium salt)
Form Sterile powder for solution for injection
Pharmacological Class Beta-Lactam antibiotic, Third-generation cephalosporin
General Purpose Bacterial elimination for severe infections
Origin Synthetic (Semi-synthetic derivative)

Defining C-Tax: Active Ingredient and Class

Cefotaxime is the synthetic active ingredient in the medicine known as C-Tax, functioning as a potent, prescription-only antibiotic. Cefotaxime is specifically classified as a third-generation cephalosporin, positioning it within the larger family of Beta-Lactam antibiotics used to eliminate bacterial pathogens. This designation is crucial as it indicates an advanced chemical structure designed for enhanced stability against bacterial defense enzymes (beta-lactamases) compared to earlier cephalosporins.

This medication maintains a broad-spectrum capability and is a semi-synthetic derivative with a defined chemical structure.

Composition, Form, and General Purpose

C-Tax is supplied as a sterile powder for solution for injection, containing the single active ingredient Cefotaxime sodium. The overarching purpose of this medicine is its bactericidal action, meaning it actively kills the invading bacteria rather than merely inhibiting their growth, which is necessary for clearing severe, systemic infections.

This function is achieved by Cefotaxime targeting the formation of the bacterial cell wall. This mechanism is of clinically recognized importance for controlling serious bacterial disease.

Why Cefotaxime is an Injectable Medicine

Cefotaxime is intended for parenteral administration via intravenous (IV) or intramuscular (IM) injection after the powder is reconstituted with a sterile base/vehicle. This delivery route is critical because it ensures the rapid and complete absorption of the antibiotic into the bloodstream, guaranteeing the high, necessary drug concentrations are achieved immediately. This is vital for the effective and timely management of serious systemic infections.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with C-Tax?

Possible Side Effects and Safety Information

The safety profile for Cefotaxime (C-Tax) is officially documented by government regulatory agencies based on System-Organ-Class (SOC) categories and frequency classifications.

Official Adverse Reaction Groupings

The adverse reactions are categorized by their documented frequency in clinical use, ranging from Common to Not Known (frequency cannot be estimated from the available data).

Frequency Classification Examples of Documented Reactions
Common Diarrhea, rash, pruritus, increase in liver enzymes, pain at the injection site (IM), phlebitis (IV).
Uncommon Eosinophilia, leukopenia, thrombocytopenia, convulsions, transient increase in serum creatinine.
Not Known Anaphylactic shock, agranulocytosis, hemolytic anemia, encephalopathy, pseudomembranous colitis, serious bullous skin reactions.

Serious adverse reactions are specifically noted in regulatory labels. These include anaphylactic shock, encephalopathy (impaired consciousness, abnormal movements), convulsions, and severe skin reactions such as Stevens-Johnson syndrome (SJS). Arrhythmias have been reported following rapid intravenous bolus infusion.

Population-Specific Safety Considerations

The official label states specific safety considerations for certain patient groups. Individuals with renal impairment are at an increased risk of neurotoxicity (encephalopathy and convulsions) due to reduced clearance of the drug. Caution is also advised in neonates with jaundice, as Cefotaxime may displace bilirubin from plasma albumin.

Safety-Related Restrictions

Cefotaxime is formally contraindicated in patients with a known hypersensitivity to the drug, to other cephalosporins, or a history of severe immediate hypersensitivity to any other beta-lactam antibacterial agent. Caution is required when the medicine is co-administered with nephrotoxic drugs (e.g., aminoglycosides) due to the potential for potentiated nephrotoxicity. For treatment courses longer than 7–10 days, monitoring of blood counts is recommended due to potential hematological effects.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the formally documented manifestations of C-Tax (Cefotaxime) overdose and the required emergency actions, based strictly on official regulatory prescribing information.

Documented Overdose Manifestations

Overdose, particularly following very high doses, primarily involves effects on the central nervous system (CNS) and gastrointestinal system.

System Regulator-Documented Clinical Signs/Symptoms
Neurological/CNS Convulsions (Seizures), Encephalopathy (e.g., impairment of consciousness, abnormal movements)
Gastrointestinal Nausea, Vomiting, Epigastric Distress, Diarrhea

Neurotoxicity is officially noted to be an increased risk in patients with renal insufficiency (impaired kidney function), which reduces the clearance of the medicine.

Required Emergency Actions

Immediate medical attention is required in the event of a suspected overdose. The official regulatory advice mandates contacting emergency services immediately if severe symptoms such as seizures, trouble breathing, or collapse occur.

Management Aspect Official Regulatory Statement
Antidote No specific antidote is documented in regulatory sources.
Treatment Treatment is supportive and symptomatic.
Procedural Steps Haemodialysis and peritoneal dialysis may be used, though their benefit is officially noted as not yet established.

Therapeutic Uses of C-Tax

What C-Tax Treats: Main Uses and Benefits

C-Tax (Cefotaxime) is a third-generation cephalosporin antibiotic commonly used across conditions presenting with acute or disruptive episodes caused by susceptible bacteria. Its clinical focus is on severe, systemic, and localized infections that are typically managed with focused therapeutic support.

Core Therapeutic Contexts

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is commonly used for conditions presenting with systemic or localized discomfort, including sepsis, bacterial meningitis, severe pneumonia, intra-abdominal infections, and complicated urinary tract infections. Its use supports the patient during difficult episodes by easing distress from symptoms related to systemic imbalance, such as persistent high fever and acute toxicity. The drug is commonly used for managing the bacterial infection, which is relevant in contexts involving heightened systemic burden.

“C-Tax is commonly used when short-term symptomatic assistance is needed for pronounced, infection-driven discomfort.”

The medication is also relevant in contexts involving heightened systemic burden for vulnerable patient groups, including neonates and immunocompromised individuals, and is a component of pre-operative prophylaxis. C-Tax contributes to easing the overall symptom load and supporting the patient during periods of organ-specific functional stress.

Quick Fact: Symptom Management
Supports the patient during difficult episodes by easing distress from systemic symptoms like persistent high fever.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

C-Tax (Cefotaxime) eligibility is determined by governmental regulatory bodies based on a patient's allergic history, developmental stage, organ function, and the specific drug formulation used.

Eligibility Scope

Eligibility Category Regulatory Status / Restriction
Populations for whom use is allowed Adults, adolescents, children, and infants, with specific maximum doses defined for neonates.
Populations for whom use is contraindicated Patients with a known history of immediate-type hypersensitivity to Cefotaxime or to other cephalosporin antibiotics.
Contr. based on other allergies Contraindicated in patients with a history of immediate-type hypersensitivity to penicillins, due to the risk of allergic cross-reactions.
Formulation-specific Contr. Contraindicated for infants under 30 months if the formulation contains Lidocaine, and prohibited in patients with Lidocaine hypersensitivity or severe heart conditions (if using the Lidocaine product).

Condition-Specific Eligibility Rules

Condition Regulatory Rule
Severe Renal Insufficiency Use is conditional and requires dosage modification to prevent accumulation of the active metabolite, desacetyl-cefotaxime.
Gastrointestinal Disease Use should be undertaken with caution in patients with a history of colitis, due to the risk of Clostridioides difficile-associated disease.
Prolonged Treatment Use requires regulatory monitoring of hematological, hepatic, and renal function if treatment extends beyond 7 to 10 days.

Pregnancy and Lactation Eligibility

The medicine is classified as US FDA Pregnancy Category B. Its use during pregnancy is officially not recommended unless the potential benefit justifies the risk to the fetus. Cefotaxime is excreted into human milk, and while generally considered acceptable, caution is advised and benefit must outweigh the risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation defines the interaction profile of Cefotaxime (C-Tax) based on altered drug disposition and potential for additive effects.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Probenecid is a documented pharmacokinetic interaction that interferes with the drug’s renal tubular transfer. This mechanism results in an officially stated increase in Cefotaxime exposure and a reduction in its clearance, classified as a clinically significant interaction.

Cefotaxime co-administration with Aminoglycosides or potent diuretics (e.g., Furosemide) carries the potential for potentiated nephrotoxic effects. Monitoring of renal function is noted as essential when combining Cefotaxime with these or other officially designated nephrotoxic drugs.

Administration and Compositional Constraints

Regulatory labels mandate several strict interaction-related restrictions:

  • Aminoglycosides must not be physically mixed with Cefotaxime in the same syringe or infusion fluid due to a documented physical incompatibility.
  • Cefotaxime reconstituted with Lidocaine Injection BP is contraindicated for intravenous administration and is prohibited for use in infants (under one year of age).
  • A drug-test interaction exists where Cefotaxime can yield false-positive results for urinary glucose tests when non-specific reducing agents are used.
  • The medicine's inherent sodium content requires consideration for patients on officially designated sodium-restricted diets (a compositional constraint).

Mechanism of Action

How C-Tax Works: Mechanistic Domains

C-Tax (Cefotaxime) exerts its effect by the targeted disruption of the bacterial cell’s structure through three core mechanistic domains.

Blocking the Cell Wall Assembly Line

Cefotaxime's primary mechanism involves the covalent inhibition of specific Penicillin-Binding Proteins (PBPs), the bacterial enzymes responsible for building the structural integrity of the cell wall. The drug selectively targets high-affinity enzymes like PBP Ib and PBP III, covalently binding to their active sites. This molecular action immediately prevents the final, critical step of peptidoglycan cross-linking, which is essential for bacterial survival.

Triggering Bacterial Self-Destruction

The structural compromise resulting from enzyme inhibition initiates a destructive mechanistic cascade: the bacterium's own autolytic enzymes (autolysins) are released from regulation. The combined failure of wall synthesis and unchecked autolysin activity causes the bacterial cell to rapidly lose its ability to manage internal osmotic pressure, leading to membrane rupture and the resulting bactericidal (cell-killing) physiological effect.

Mechanistic Stability Against Defense Enzymes

The molecule's chemical structure, specifically its oxyimino group, provides a critical defense against many common beta-lactamase enzymes. This stability ensures the molecule remains chemically intact long enough to reach and bind to its PBP targets, preserving its bactericidal capacity in the face of bacterial resistance mechanisms.

Dosage and Administration Information

C-Tax (Cefotaxime) is administered exclusively via parenteral routes, which include intravenous (IV) injection, IV infusion, and intramuscular (IM) injection, after its sterile powder form is dissolved with a suitable solvent. The use of the parenteral route ensures rapid systemic drug delivery, supporting its application in settings requiring high concentration.

The official dosing schedule is determined by the severity of the infection being addressed. For mild to moderate infections, the standard regimen involves 1 g every 12 hours. Dosing increases for severe infections to 1 g to 2 g every 8 hours, and for life-threatening conditions, the dose may be escalated up to a maximum of 2 g every 4 to 8 hours, not to exceed 12 grams daily. The total treatment duration is generally continued for a further three to four days after the signs of infection have resolved.

Administration requires specific procedural adherence. IV bolus injection must be administered slowly over a minimum of three to five minutes, or as an infusion over 20 to 60 minutes. Furthermore, the label requires dosage adjustment for patients with severe renal impairment. The maintenance dose is halved following a 1 g loading dose. When administering intramuscularly, the dose should not exceed 1 g per single injection site. It is also explicitly stated that C-Tax must not be physically mixed with aminoglycosides in the same solution.

Recent Clinical Evidence

Research Evidence / Overview of Studies for C-Tax (Cefotaxime)

Evidence for Core Indications and Outcomes

The research base for C-Tax (Cefotaxime) includes Randomized Controlled Trials (RCTs) exploring its role in managing severe systemic infections like bacterial meningitis and severe sepsis. These studies monitored critical outcomes, including patient survival and the clearance of infection in the central nervous system or bloodstream. Cefotaxime was also evaluated for serious localized infections, such as severe pneumonia and complicated intra-abdominal infections, with research focusing on clinical and bacteriological success rates. For these localized infections, studies often used composite endpoints, which means that multiple health measures were tracked together.

Evidence in Special Populations and Limitations

Specific research has explored Cefotaxime in vulnerable patient groups, including neonates, infants, and critically ill adults. This work often involves Pharmacokinetic/Pharmacodynamic (PK/PD) studies that evaluate target drug concentrations, which are necessary due to the high variability in drug clearance in these patients. Research suggests follow-up durations were limited in many studies, meaning that long-term effects are not fully established regarding the durability of treatment. Ongoing research focuses on the impact of rising global rates of bacterial resistance on observed clinical patterns, and comparative evidence is lacking for some of the newest antibiotics.

Key Studies & References

  1. The selection and use of essential medicines (WHO Model List of Essential Medicines) – Cefotaxime
  2. Clinical Pharmacology of Cefotaxime in Neonates and Infants: Effects and Pharmacokinetics
  3. Pneumonia: diagnosis and management (NICE Guideline NG250)

How should C-Tax be stored and disposed of?

The storage and disposal of Cefotaxime Sodium (C-Tax) must adhere to official label specifications to maintain stability and prevent environmental contamination.

Storage Requirements

Product Form Temperature / Protection Stability Constraint
Dry Powder Controlled room temperature (20 C to 25 C); Protect from light and excessive heat. Must be stored in the original outer carton.
Reconstituted Solution Room temperature (e.g., le 22 C) or refrigerated (2 C to 8 C). Stability is limited to 12–24 hours at room temperature or 5–7 days refrigerated. Thawed solutions must not be refrozen.

Disposal and Handling

All medicines must be kept out of the sight and reach of children. The unused portion of the solution must be discarded after the labeled stability period. Unused or expired Cefotaxime should not be thrown into wastewater or household trash and must be disposed of according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of C-Tax found in:

A-Z Index: